Forecast: Renin-Angiotensin System Medicine Sales in Italy

As of 2023, the Renin-Angiotensin System Medicine sales in Italy were slightly below 2.06 billion USD PPP. From 2024 onwards, the sales are forecasted to gradually increase, reaching 2.31 billion USD PPP by 2028. This indicates a steady year-on-year growth trend, averaging around 2-3% annually. Over the forecast period, the compound annual growth rate (CAGR) is projected to be moderate, pointing towards a stable demand for these medicines.

Future trends to watch for include:

• Potential regulatory changes impacting market dynamics.
• Innovations in alternative therapies and their market penetration.
• Healthcare policy reforms that could influence healthcare spending.
• Evolving demographic factors driving healthcare demand in Italy.